##  [Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients](/us-en/news/media-releases/novartis-baf312-reduced-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients-0 "Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients") 

  Sep 17, 2016